Samsung Bioepis enters novel drug space via Takeda deal

Samsung Bioepis Co. Ltd. is expanding its focus beyond biosimilars to discover, develop and commercialize novel biologics. The company will start to build its novel pipeline via collaborations, including its first co-development deal with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), which was announced Aug. 21.

The partners will jointly fund and co-develop multiple biologic therapies for diseases with unmet needs, starting with TAK-671 to treat severe acute pancreatitis. Details of the program are undisclosed...